US45337C1027 - Common Stock
INCYTE CORP
NASDAQ:INCY (4/25/2024, 1:01:09 PM)
51.15
-0.59 (-1.14%)
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,324 full-time employees. The firm also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland, and Japanese office in Tokyo and Canadian headquarters in Montreal. The company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream.
INCYTE CORP
1801 Augustine Cut-Off
Wilmington DELAWARE 19803
P: 13024986700
CEO: Herve Hoppenot
Employees: 2324
Website: https://www.incyte.com/
Don't overlook INCYTE CORP (NASDAQ:INCY)—it's a hidden gem with strong fundamentals and an attractive price tag.
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements.
Here you can normally see the latest stock twits on INCY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: